Every year, as the seasons change, Respiratory Syncytial Virus (RSV) remains a silent but persistent threat. It is one of the leading causes of serious lower respiratory tract infections, including bronchiolitis and pneumonia, in newborns and young children. During the first six months of life, when a baby’s immune system is still developing, RSV infections are more likely to become severe. In some cases, this may require hospitalisation and can lead to long-term health effects later in childhood.

With the aim of providing a safe protective shield from the very first days of life, FV Hospital is now offering RSV monoclonal antibody immunisation with Beyfortus, scientifically known as Nirsevimab. This new-generation biological product is widely used in developed countries and is recommended by the US Centers for Disease Control and Prevention (CDC). As an advanced therapy, it provides rapid protection for children shortly after administration.

How is the RSV monoclonal antibody different from a vaccine?

• How it works: Unlike vaccines, which introduce a weakened part of the virus into the body to stimulate the immune system to produce its own antibodies, the RSV monoclonal antibody is a ready-made antibody created in a laboratory. It provides immediate immune protection after administration, making it particularly suitable for newborns and young children whose immune systems are not yet fully developed.
• Key features: This monoclonal antibody specifically targets the RSV virus and provides protection for an average of around six months. The timing of administration can be flexible, depending on each family’s needs. This is particularly important in Vietnam, where RSV circulates throughout the year. As a result, it is an effective option for protecting infants during the most vulnerable early months of life.

At what age can children receive the RSV monoclonal antibody at FV?

• Children from 1 day old up to 24 months of age.
• The dose depends on the child’s body weight, with different dosing for children under 5 kg or those weighing 5 kg and above.

Why choose RSV monoclonal antibody at FV Hospital?

• The RSV monoclonal antibody is a biological product that must be administered in a medical facility fully equipped to manage emergency situations. At FV Hospital, accredited by the Joint Commission International (JCI) for four consecutive terms, parents can feel completely reassured about safety and quality standards.
• FV’s vaccination area is located within the hospital campus and is supported by a full emergency response system, continuous monitoring, and specialist doctors who are always on hand to provide immediate care if needed.
• FV doctors have extensive experience in monitoring and caring for newborns, premature babies, and children with underlying medical conditions. This ensures careful assessment before administration and appropriate follow-up after treatment.
• The RSV monoclonal antibody is safely stored and readily available at FV Hospital’s Pharmacy Department. Parents do not need to wait, helping ensure timely protection for their child.

According to Dr Nguyen Thi Dieu Huyen, MSc, Head of Paediatrics and Neonatology at FV: “FV Hospital currently has the RSV monoclonal antibody available for children. We place strong emphasis on medical quality and family peace of mind, especially for newborns and children with underlying conditions, when administration is carried out in FV’s safe and well-regulated hospital environment.”

For more information or to book an appointment, please contact the Paediatrics and Neonatology Department at FV Hospital.

Tel: 028 35 11 33 33